Table 4

Sensitivity analysis: classes of participants with chronic back pain suspicious of axial spondyloarthritis identified in the 2-year latent transition analysis model in the population with complete follow-up (n=384)

Class 1 'axial' (p*=0.25, N†=96)Class 2 'IBP+peripheral' (p*=0.15, N†=58)Class 3 'at risk' (p*=0.31, N†=119)Class 4 'no SpA' (p*=0.29, N†=111)
Sacroiliitis on MRI-SIJ (ASAS)1.000.260.070.05
BME on MRI-Spine (≥5 lesions)0.100.020.000.01
Definitive damage on X-SIJ (mNY)0.100.030.020.01
≥1 syndesmophyte on X-Spine0.090.230.100.12
Elevated CRP (>5 mg/L)0.500.440.290.24
Good response to NSAID ever0.600.730.540.51
Peripheral arthritis ever0.140.780.000.13
Dactylitis ever0.080.450.030.01
Heel pain ever0.180.800.140.23
Family history of SpA0.450.591.000.00
Psoriasis ever0.090.500.070.08
Uveitis ever0.150.080.100.10
Inflammatory bowel disease ever0.040.080.070.10
Inflammatory back pain ever0.800.980.780.86
  • Conditional probabilities (ie, the probability of a feature being present in one of the classes, range: 0–1) were obtained using a latent transition analysis model with full invariance on baseline and 2-year data. Full invariance means that these probabilities are the same at baseline and follow-up.

  • Cells are coloured in green whenever the conditional probability is ≥0.3. This cut-off was chosen to better visualise differences between the classes.

  • *Marginal probability of the latent class (ie, a participant’s probability of class membership).

  • †Participants categorised to one of the classes based on their posterior probability of class membership (with the class having the highest probability for each patient determining their assignment).

  • ASAS, Assessment of SpondyloArthritis international Society; BME, bone marrow oedema; CRP, C reactive protein; IBP, inflammatory back pain; mNY, modified New York criteria; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joints; SpA, spondyloarthritis; X-SIJ, radiograph of the sacroiliac joints; X-Spine, radiograph of the spine.